Dec 03, 2020 / 03:00PM GMT
Francois R. Martelet - Oasmia Pharmaceutical AB(publ)-CEO
Thank you. So it's Francois Martelet, CEO of Oasmia. So good afternoon, everyone. So today, I'm very pleased to introduce you to what I would consider an exceptional analyst and investor live event as we have with us 2 very distinguished guests from Elevar: so Alex Kim, CEO of Elevar; and Mark Gelder, Head of Medical Affairs. Both have very kindly accepted to share with you the strategy of the indication in the U.S. that they will be implementing in the next following months.
So if you go to Slide #4, so Alex Kim will go through the Apealea as an overview. That will be followed by Mark Gelder going through the ovarian cancer indication, the current treatment and the future treatment as well and also advancing the Apealea development program as a follow-up after the overview of the current treatment gaps. And then we will have a Q&A session at the very end of this presentation.
So before I will go -- I will give the floor to Alex, perhaps on the Slide #6, just would like to say a few words
LSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call Transcript
Mar 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers